Balancing cost:benefit in ‘well-treated’ malignancies

24 January 2018

Pharmaphorum has recently published an article from THE PLANNING SHOP titled ‘Balancing cost:benefit in ‘well-treated’ malignancies’. The article was written by Jeremy Smith, an Associate Director based in our US office.

Jeremy discusses the cost:benefit ratio of the rising prices of new oncology treatments and how the pharmaceutical industry and regulators can adequately address them while still promoting R&D.

You can read the article by clicking here.

Please contact us on or 020 8231 6888 if you’d like more information.